Oruka Therapeutics Inc (ORKA) Stock Analysis
Verdict: HOLD
ORKA's long-acting antibody pipeline offers potent I&I market potential, but valuation hinges entirely on Phase 2 trial readouts.
Investment score: 54/100
Analysis as of
Is Oruka Therapeutics Inc stock worth reviewing? AI model thesis
Oruka Therapeutics (ORKA) is a clinical-stage biopharmaceutical firm advancing extended half-life antibodies targeting IL-23 (ORKA-001) and IL-17A/F (ORKA-002) for psoriasis. While backed by a strong cash runway (~3.5 years based on 2025 burn) and unanimous analyst enthusiasm ($149.56 average price target), zero commercial revenue, heavy insider selling, and high clinical trial dependency keep the risk profile elevated.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Oruka Therapeutics Inc opportunities and risks
What speaks for ORKA
- Extended Half-Life Advantage in Multi-Billion Dollar I&I Markets
What speaks against ORKA
- Binary Phase 2 Clinical Readout Failure Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ORKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.8% |
| RYTM | n/a | 28.0x | n/a | 89.0% | -85.6% | -2.2% |
| CGON | n/a | 1049.7x | n/a | -82.7% | -3602.7% | -2.7% |
| MIRM | n/a | 9.6x | n/a | 81.7% | -139.2% | -7.7% |
| SRRK | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| TVTX | n/a | 10.0x | 4146.6x | 94.4% | -7.4% | 0.9% |
| Peer median | n/a | 10.0x | n/a | 81.7% | -85.6% | -2.7% |
Frequently asked questions about Oruka Therapeutics Inc (ORKA)
Is ORKA stock a good investment?
The cached TradeMates AI model rates Oruka Therapeutics Inc as HOLD with an investment score of 54/100. Oruka Therapeutics (ORKA) is a clinical-stage biopharmaceutical firm advancing extended half-life antibodies targeting IL-23 (ORKA-001) and IL-17A/F (ORKA-002) for psoriasis. While backed by a strong cash runway (~3.5 years based on 2025 burn) and unanimous analyst enthusiasm ($149.56 average price target), zero commercial revenue, heavy insider selling, and high clinical trial dependency keep the risk profile elevated. This is algorithmic model output, not personal investment advice.
Is ORKA stock a buy?
The TradeMates model verdict for ORKA is HOLD with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.